

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 6185)**

**INSIDE INFORMATION**

**HEALTH CANADA ACCEPTED PRE-CTA MEETING REQUEST  
FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS  
TYPE 5 VECTOR)**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that the Company submitted the pre-clinical trial application meeting request (the “**pre-CTA Meeting Request**”) to Health Canada for Recombinant Novel Coronavirus Disease Vaccine (Adenovirus Type 5 Vector) (the “**Ad5-nCoV**”) on April 24, 2020, and Health Canada accepted the pre-CTA Meeting Request. The Company plans to conduct clinical trial for Ad5-nCoV with partners in Canada after the clinical trial application is approved.

Ad5-nCoV is a genetic engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein, which intends to be used to prevent the disease caused by the novel coronavirus infection. Currently, the Ad5-nCoV is ongoing phase I and phase II clinical studies in China.

**Cautionary Statement required by Rule 18A.05 of the Listing Rules:** The safety and efficacy of Ad5-nCoV is subject to confirmation by clinical trials and we cannot guarantee that we will ultimately develop or market Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, April 27, 2020

*As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.*